Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Docetaxel
Drug ID BADD_D00699
Description Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio
Indications and Usage For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Marketing Status Prescription; Discontinued
ATC Code L01CD02
DrugBank ID DB01248
KEGG ID D02165
MeSH ID D000077143
PubChem ID 148124
TTD Drug ID D0O5WP
NDC Product Code 0955-1022; 67457-781; 45963-765; 47335-323; 57884-3042; 66758-050; 43598-611; 43598-258; 54893-0008; 0409-5068; 43598-389; 55150-378; 0955-1020; 72485-214; 0409-0368; 70700-176; 68083-401; 70700-174; 65129-1189; 70121-1223; 65129-1298; 0143-9204; 65129-1141; 47335-895; 0143-9205; 55150-379; 57884-3041; 47335-939; 70121-1222; 70700-175; 0409-4235; 17359-9100; 0409-0367; 16729-267; 68083-400; 68554-0075; 43066-001; 0409-0365; 43066-010; 72485-215; 66758-950; 43598-259; 55150-380; 70747-1004; 68083-399; 70121-1221; 45963-734; 0955-1021; 0409-0366; 43066-006; 43598-610; 72485-216; 57884-3043
Synonyms Docetaxel | Docetaxel Trihydrate | Docetaxol | Docetaxel Hydrate | Taxoltere Metro | RP 56976 | RP-56976 | RP56976 | Taxotere | Docetaxel Anhydrous | N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol | N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol | NSC 628503
Chemical Information
Molecular Formula C43H53NO14
CAS Registry Number 114977-28-5
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O) O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cell deathApoptosis regulator Bcl-2P10415T31309Not Available
Cell deathCaspase-3P42574T57943Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.0040.002398%Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.002--Not Available
Lung disorder22.02.07.0010.000799%Not Available
Lymphoedema24.09.01.001; 01.09.01.0060.000799%
Lymphopenia01.02.02.002--Not Available
Macular degeneration06.09.03.0010.000533%Not Available
Macular oedema06.04.06.0050.000533%Not Available
Maculopathy06.09.03.0070.001598%Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.0040.000799%Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Menopausal symptoms21.02.02.002--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Mental impairment19.21.02.003; 17.03.03.0020.000533%Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.000139%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mouth ulceration07.05.06.0040.000533%Not Available
Mucosal inflammation08.01.06.0020.005328%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.0070.000799%
Myalgia15.05.02.0010.002398%
Myelodysplastic syndrome16.01.04.001; 01.10.04.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Myositis15.05.01.0010.000208%
Nail discolouration23.02.05.001--
Nail disorder23.02.05.0020.001332%
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 15 Pages